Introduction: Male breast cancer (MBC) is a rare condition, which accounts for less than 1% of all breast cancer diagnoses. Because of this, there is a paucity of focussed work available and most data is derived from female breast cancer studies. Recently, there has been speculation of increased incidence, and we sought to verify this by reviewing our own experience with MBC.
INTRODUCTION
Male breast cancer (MBC) is a reasonably uncommon malignancy and accounts for less than 1% of all breast cancer diagnoses [1] . Because of the relative rareness of this condition, there is little focussed work available for review, with very few prospective trials actively being undertaken [2] . Consequently, the majority of the current information on this condition has been derived from retrospective analyses spanning many years [3] , and therapeutic options have been obtained from results of trials on patients with female breast cancer (FBC).
Recently, there has been renewed interest in MBC, due to reports of increasing incidence being observed [4] . Based on our regional population in Mid-Western Ireland of 361 028, with males accounting for 182 296 (based on Central Statistics Office data (www.cso.ie), we see on average two hundred (200) new FBC per annum, and by extrapolation from the literature, we should see two (2) These data were cross-referenced with the National Cancer Registry in Ireland (www.ncri.ie) and revealed that eight (8) patients were diagnosed within the region, but only seven (7) were reviewed at MWRH.
RESULTS
There were seven (7) patients identified. The mean age at presentation was 66.6 years, with standard deviation of 10.5 years, and a range of 44-76 years. The presenting features were reviewed, and all patients were found to have breast lumps detected on self-examination. None of the patients were reported to having mastalgia, bleeding, discharge, skin nodules or inflammatory changes in the breast area. The family, drug and treatment histories were also reviewed and the information is shown in Table 1 . With respect to the family history for BRCA1/2 and PTEN, these patients were reviewed for cancer risk at the National Centre for Genetic Testing, Dublin, Ireland and were found not to have sufficient indications for formal genetic testing. Of the three patients with family history for malignancy, all were within first degree relatives, and the types of malignancies included prostate cancer, lung cancer and Hodgkin lymphoma in JN, gastric cancer in PN and female breast cancer in PS. Of interest two (2) patients were treated with digoxin (oestrogen-like agent, known to cause gynaecomastia with long-term usage) for prolonged period (PN for more than ten years at dose of 0.125mg and PS for more than six years, at same standard dose of 0.125mg) and one (1) patient had undergone thoracic irradiation 30 years previously for Hodgkin lymphoma.
The histopathological features of the tumours were reviewed, and 6 out of the 7 patients had histological confirmation of their diagnoses. One patient's diagnosis was established on clinical and radiological grounds, because of his frail condition. He has subsequently passed away within a few days of his initial assessment. All the sampled tumours were found to be ductal carcinomas, with 100% of these being oestrogen receptor positive and 86% of these being progesterone receptor positive and only 1 patient had been tested for her2-neu mutation. The data is shown in Table 2 .
The therapeutic options received by the patients were reviewed and the information is shown in Table 3 .
The mean follow-up for all patients involved was 19.9 months with a range of 0-60 months. The survival data for patients was obtained, but given the small numbers of patients the interpretation was not statistically appropriate.
The features as stated in the literature are shown in the Table 4 .
DISCUSSION
MBC is a relatively rare condition, and therefore it would be extremely difficult to embark on large-scale prospective studies on standards of care, where the results were statistically valid and could be easily reproduced. Several retrospective studies have been published over the years, and this review serves to add a small cohort to those already available in the literature.
The main objective was to elucidate our experience and to see how it compared to established information. Our results have revealed that the age of presentation for MBC patients was 66.6 years, and was greater than that of FBC patients. This finding was comparable to findings in the literature [5, 6] . The incidence of MBC, like that of most cancers increases with advancing age of the patient, until it reaches a maximum at about the age of 80 years [7] .
Our results have also revealed that a painless lump was the main presenting feature for all our patients. This is higher than for FBC, and maybe due to several factors including our sample size or the anatomical nature of the male and female breast or the fact that breast cancer screening is available for women and can potentially detect lesions before they become palpable. This feature also compares with those listed in the published literature [8] .
Unlike the published data, where there is a left-sided versus right-sided disease preponderance [9] , our results revealed a right sided preponderance. The significance of this is undetermined, but may only reflect our small sample size.
No family history of BRCA1, BRCA2 or PTEN mutations were noted within our cohort, following the preliminary assessments, however 4/7 (57%) of patients had a family history of malignancy, including prostate cancer, lung cancer, Hodgkin lymphoma, gastric cancer and FBC. Mutations in BRCA1 and BRCA2 have been noted to increase the risk of affected patients developing MBC, although not to the same absolute risk as in patients with FBC [10] . In population-based studies on MBC, BRCA1 mutations were found in 0-4% patients [11] . Mutations in BRCA2 gene are noted to be more frequent than BRCA1, in patients with MBC, with a range of 4-16% being noted in population-based studies [12] . MBC in patients with BRCA2 mutations are noted to present at a younger age and 100% of these are noted to have a poorer outcome, when compared to patients without BRCA2 mutations [13] . It can also be noted that men with a family history of FBC have an increased risk of developing MBC [14] , this was seen with one of our patients, but assessing the risk in this case was not possible. One of our patients with MBC, also gave a history 30 years prior of having undergone thoracic irradiation for Hodgkin lymphoma, which has been established as an increasing potential risk [15] .
These results have revealed that all patients had ductal carcinoma, this is more likely to be due to the sample size, although review in the literature show that as much as 90% of MBC are ductal in origin [4] . This distribution is greater than listed for FBC is approximately 80% [16] . It was seen that within our dataset of patients with histological information, that oestrogen receptor expression was 100% and progesterone receptor expression was 86%. This information compares to the high receptor expression seen in the literature, where oestrogen receptor expression was 90% and progesterone receptor expression was 81% [10] . This is higher than seen in FBC, even with adjustment for tumour stage, grade, and age of presentation [10] . There was only information on one patient with her2-neu over-expression within our group, he was not offered adjuvant biological therapy with trastuzumab as there is no official guidance on this. Within the literature, only low levels of her2-neu overexpression is seen in 0-5% of male patients [17, 18] . Nottingham prognostic index (NPI) was not formally reviewed in any of the reviews readily available and has only been used in female breast cancer patients, but within our cohort, it was revealed that those with corresponding values, had a good expectation for outcome. This observation very much correlated with the overall survival curves.
This retrospective review is limited by the number of patient's samples found within our unit at MWRH, but it does offer good insight into our patient demographics, that compares with data available in the literature. The question on the role of adjuvant chemotherapy or biological Kwiatkowska et al. [13] 
